Alpha-Cyclodextrin Sulforaphane Crystals for Ambient Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Sulforaphane's chemical instability hinders its development as a pharmaceutical agent due to rapid degradation under ambient conditions, making it difficult to manufacture, formulate, and distribute.
Innovation Solution
A crystalline complex of sulforaphane and alpha-cyclodextrin with low water content and improved stability is developed, maintaining stability over a range of ambient humidity conditions, characterized by specific X-Ray Powder Diffraction peaks and formed through controlled drying under reduced pressure with agitation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If sulforaphane is complexed with cyclodextrins to stabilise it, then stability is improved, but water content increases which reduces long-term stability under ambient humidity conditions
Solution Approach 1:
The patent applies parameter changes by controlling the water content of the cyclodextrin complex to less than 8% w/w through specific drying processes. This parameter optimization resolves the contradiction by reducing water content to a level that enables long-term stability under ambient humidity conditions (up to 70% RH) while preserving the stabilizing effect of cyclodextrin complexation.
Solution Approach 2:
The patent employs preliminary action through controlled drying processes performed before final formulation and storage. By removing excess water content in advance through vacuum drying or other appropriate methods, the complex is prepared in a stable state that prevents degradation during subsequent storage and distribution under ambient conditions.
2Stability of the object's composition
If sulforaphane is stabilized through complexation with cyclodextrins, then chemical instability is reduced, but the complexity of manufacture and formulation increases
Solution Approach 1:
The patent uses cyclodextrins as intermediary molecules that form stable inclusion complexes with sulforaphane. This intermediary approach protects the unstable sulforaphane molecule through the cyclodextrin cavity, enabling easier handling, storage, and formulation while maintaining therapeutic efficacy. The complex acts as a mediator that simplifies downstream processing despite the initial complexity of complexation.
3Ease of operation
If sulforaphane is stored under ambient conditions, then handling and storage is simplified, but rapid degradation occurs
Solution Approach 1:
The patent creates an inert protective environment through cyclodextrin complexation, where the cyclodextrin molecules form a protective cavity around sulforaphane. This inert-like environment shields the sensitive sulforaphane from ambient conditions (oxygen, moisture, light), enabling stable storage and handling under normal ambient conditions without special protective measures.
Data Source
AI summary
The present invention relates to crystalline complexes of sulforaphane and alpha-cyclodextrin; pharmaceutical compositions comprising the complexes; methods for their manufacture; and the use of said complexes as a medicament.